HK1258128A1 - 選擇病人接受組合療程 - Google Patents

選擇病人接受組合療程 Download PDF

Info

Publication number
HK1258128A1
HK1258128A1 HK19100418.3A HK19100418A HK1258128A1 HK 1258128 A1 HK1258128 A1 HK 1258128A1 HK 19100418 A HK19100418 A HK 19100418A HK 1258128 A1 HK1258128 A1 HK 1258128A1
Authority
HK
Hong Kong
Prior art keywords
combination therapy
patients
selection
entinostat
methods
Prior art date
Application number
HK19100418.3A
Other languages
English (en)
Chinese (zh)
Inventor
Peter Ordentlich
Original Assignee
Syndax Pharmaceuticals Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Syndax Pharmaceuticals Inc. filed Critical Syndax Pharmaceuticals Inc.
Publication of HK1258128A1 publication Critical patent/HK1258128A1/zh

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hospice & Palliative Care (AREA)
  • Physiology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
HK19100418.3A 2015-09-02 2016-09-02 選擇病人接受組合療程 HK1258128A1 (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562213288P 2015-09-02 2015-09-02
US201562213288P 2015-09-02
US201562219612P 2015-09-16 2015-09-16
US201562219612P 2015-09-16
PCT/US2016/050274 WO2017041043A1 (en) 2015-09-02 2016-09-02 Selection of patients for combination therapy

Publications (1)

Publication Number Publication Date
HK1258128A1 true HK1258128A1 (zh) 2019-11-08

Family

ID=58188549

Family Applications (1)

Application Number Title Priority Date Filing Date
HK19100418.3A HK1258128A1 (zh) 2015-09-02 2016-09-02 選擇病人接受組合療程

Country Status (14)

Country Link
US (2) US11397184B2 (enExample)
EP (1) EP3345002A4 (enExample)
JP (2) JP2018527570A (enExample)
KR (2) KR20240017973A (enExample)
CN (2) CN108139403B (enExample)
AU (2) AU2016318136B2 (enExample)
BR (1) BR112018003238A2 (enExample)
CA (1) CA2994731C (enExample)
HK (1) HK1258128A1 (enExample)
IL (1) IL257355B (enExample)
MX (1) MX2018002640A (enExample)
RU (1) RU2018111407A (enExample)
WO (1) WO2017041043A1 (enExample)
ZA (1) ZA201800931B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018508593A (ja) * 2015-03-20 2018-03-29 シンダックス ファーマシューティカルズ，インコーポレイティド がんを処置するためのｈｄａｃ阻害剤および抗ｐｄ−１抗体の組合せ
EP3407913A1 (en) 2016-01-28 2018-12-05 Indiana University Research & Technology Corporation Use of histone deacetylase inhibitors for enhancing immunotherapies
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
CN109715173A (zh) 2016-07-15 2019-05-03 维拉克塔治疗公司 供基于nk细胞的疗法使用的hdac抑制剂
EP3624848A1 (en) 2017-05-19 2020-03-25 Syndax Pharmaceuticals, Inc. Combination therapies
CN112513636A (zh) * 2018-05-07 2021-03-16 赛达克斯制药股份有限公司 用于组合疗法的患者的选择
CN109251891B (zh) * 2018-09-21 2021-10-22 苏州大学附属第一医院 一种cd40联合pd-l1及细胞因子扩增pbmc的方法
CN117054649A (zh) * 2023-08-04 2023-11-14 广州中医药大学第一附属医院 一种慢性萎缩性胃炎向胃癌转化标志物及其应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4410545A (en) 1981-02-13 1983-10-18 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4328245A (en) 1981-02-13 1982-05-04 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4409239A (en) 1982-01-21 1983-10-11 Syntex (U.S.A.) Inc. Propylene glycol diester solutions of PGE-type compounds
US6350458B1 (en) 1998-02-10 2002-02-26 Generex Pharmaceuticals Incorporated Mixed micellar drug deliver system and method of preparation
ITUD20080058A1 (it) * 2008-03-18 2009-09-19 Thankstem S R L Kit per la raccolta di sangue, preferibilmente periferico, per la produzione di cellule staminali
GB201015765D0 (en) 2010-09-21 2010-10-27 Immatics Biotechnologies Gmbh Use of myeloid cell biomarkers for the diagnosis of cancer
CN109517897A (zh) * 2011-04-28 2019-03-26 南加利福尼亚大学 人类髓源抑制性细胞癌症标记
EP3381454A1 (en) 2011-09-02 2018-10-03 Syndax Pharmaceuticals Inc. Methods for the treatment of breast cancer
AU2013290237A1 (en) 2012-07-10 2015-01-22 Dana-Farber Cancer Institue, Inc. Anti-proliferative compounds and uses thereof
CA2886650A1 (en) * 2012-11-29 2014-06-05 The Penn State Research Foundation Photodynamic dhsip anticancer therapeutic and immunomodulator
CN107072984B (zh) 2014-07-15 2021-10-01 约翰·霍普金斯大学 源自骨髓的抑制细胞的抑制和免疫检查点阻断
JP2018508593A (ja) * 2015-03-20 2018-03-29 シンダックス ファーマシューティカルズ，インコーポレイティド がんを処置するためのｈｄａｃ阻害剤および抗ｐｄ−１抗体の組合せ

Also Published As

Publication number Publication date
EP3345002A4 (en) 2019-05-08
MX2018002640A (es) 2018-06-20
CN108139403B (zh) 2023-05-09
WO2017041043A1 (en) 2017-03-09
CN116893262A (zh) 2023-10-17
CN108139403A (zh) 2018-06-08
EP3345002A1 (en) 2018-07-11
US20230061048A1 (en) 2023-03-02
US20180252721A1 (en) 2018-09-06
KR20180048703A (ko) 2018-05-10
US11397184B2 (en) 2022-07-26
KR102631377B1 (ko) 2024-01-29
RU2018111407A3 (enExample) 2020-02-10
CA2994731C (en) 2023-09-26
JP2022009460A (ja) 2022-01-14
ZA201800931B (en) 2023-12-20
AU2022246409A1 (en) 2022-11-03
AU2016318136B2 (en) 2022-10-20
AU2016318136A1 (en) 2018-02-22
IL257355A (en) 2018-04-30
BR112018003238A2 (pt) 2018-09-25
KR20240017973A (ko) 2024-02-08
RU2018111407A (ru) 2019-10-03
CA2994731A1 (en) 2017-03-09
JP7206352B2 (ja) 2023-01-17
JP2018527570A (ja) 2018-09-20
IL257355B (en) 2021-10-31

Similar Documents

Publication Publication Date Title
HK1258128A1 (zh) 選擇病人接受組合療程
EA201691866A1 (ru) Проникающие в опухоль лимфоциты для адоптивной клеточной терапии
EP4218778A3 (en) Diagnostic methods for t cell therapy
PH12017502154A1 (en) Methods for conditioning patients for t cell therapy
BR112017010761A2 (pt) tratamento de doenças associadas à ativação de célula estrelada hepática com o uso de terapias de redução de amônia
MX2018002723A (es) Macrociclicos peptidomimeticos y usos de los mismos.
EP3229586A4 (en) Genetically modified cells, tissues, and organs for treating disease
MY192999A (en) Combination therapy of t cell activating bispecific antigen binding molecules and pd-1 axis binding antagonists
BR112018008390A2 (pt) composições e métodos para transdução tumoral
EP3135374A4 (en) Ion exchange membrane, ion exchange membrane laminated body provided with ion exchange membrane, electrochemical cell provided with ion exchange membrane laminated body, and water treatment apparatus provided with electrochemical cell
EP3645708A4 (en) COMPOSITIONS AND METHODS OF ADOPTIVE CELL THERAPY FOR CANCER
HK1221424A1 (zh) 治疗癌症的药物组合
IL276406A (en) Osimertinib for use in the treatment of non-small cell lung cancer
EP3273977A4 (en) Nk-92 cells in combination therapy with cancer drugs
WO2017027391A3 (en) Genetic abnormalities in plasma cell dyscrasias
SG11202101071WA (en) Proton therapy gantry
EP3303402A4 (en) ANTIBODIES TO GLYPICAN-3 AND ITS USE TO CANCER DIAGNOSIS AND TREATMENT
WO2018009904A3 (en) Compositions and treatment methods for cancer immunotherapy
IL254228A0 (en) Cell therapy agent for cancer treatment and combined therapy with it
EP3999080C0 (en) MONOCYTES EXPRESSING P21 FOR CANCER CELL THERAPY
HK1257882A1 (zh) 通过t细胞疗法来治疗多发性骨髓瘤和浆细胞性白血病的方法
MX384069B (es) Biomarcadores para una terapia combinada que comprende lenvatinib y everolimus.
WO2015042446A3 (en) Compositions and methods for the analysis of radiosensitivity
HK1259030A1 (zh) 具有抗趋除特性的修饰的天然杀伤细胞及其用途
HK40043274A (en) Osimertinib for use in the treatment of non-small cell lung cancer

Legal Events

Date Code Title Description
AM Amended specification (according sect 146 of patent law)

Free format text: CORRECTION OF THE ENGLISH NAME OF THE APPLICANT

Effective date: 20250516